BTAI ▼ -16.7% - BioXcel Therapeutics, Inc. $BTAI - BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals BioXcel Therapeutics shares fell 16.7% following the company's announcement of an asset sale agreement with Teva Pharmaceuticals. While the headline doesn't specify which assets are being divested or the financial terms, investors typically react negatively to asset sales, which can signal financial pressure, reduced future revenue streams, or a strategic pivot away from core business lines. The magnitude of the decline suggests the market views this transaction as materially negative for the company's prospects. 28-AUG-2026 06:00 AM ET